All Programs

Use the tool below to view all available Global Cardiology Academy Series

Value of of Earlier Lipid-Lowering therapy Intensification with Evolocumab in High-Risk Populations without known significant ASCVD and with Diabetes: VESALIUS-CV Insights
Value of of Earlier Lipid-Lowering therapy Intensification with Evolocumab in High-Risk Populations without known significant ASCVD and with Diabetes: VESALIUS-CV Insights
Cardiology
Value of of Earlier Lipid-Lowering therapy Intensification with Evolocumab in High-Risk Populations without known significant ASCVD and with Diabetes: VESALIUS-CV Insights
- Dr. Robert Giugliano
Athlete-Focused CPET: Interpreting Physiology Beyond Standardized Testing
Athlete-Focused CPET: Interpreting Physiology Beyond Standardized Testing
Heart Matters
Athlete-Focused CPET: Interpreting Physiology Beyond Standardized Testing
- Benjamin Levine, MD, FACC
Understanding CPET for Athletes: Protocols and Pitfalls
Understanding CPET for Athletes: Protocols and Pitfalls
Heart Matters
Understanding CPET for Athletes: Protocols and Pitfalls
- Benjamin Levine, MD, FACC
Examining Barriers to Digital Healthcare in PAH
Examining Barriers to Digital Healthcare in PAH
Clinician's Roundtable
Examining Barriers to Digital Healthcare in PAH
- Daniel Lachant, D.O.
Advances in Sports Cardiology: Updates from ACC 2026
Advances in Sports Cardiology: Updates from ACC 2026
Heart Matters
Advances in Sports Cardiology: Updates from ACC 2026
- Jeffrey Hsu, MD, PhD
Counseling Patients on Disease Progression in ATTR-CM
Counseling Patients on Disease Progression in ATTR-CM
Heart Matters
Counseling Patients on Disease Progression in ATTR-CM
- Joban Vaishnav, MD
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Heart Matters
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Rethinking Thromboembolic Risk in ATTR-CM Care
Rethinking Thromboembolic Risk in ATTR-CM Care
Heart Matters
Rethinking Thromboembolic Risk in ATTR-CM Care
Fatty Acid Profiles May Be Linked to PAH Risk
Fatty Acid Profiles May Be Linked to PAH Risk
AudioAbstracts
Fatty Acid Profiles May Be Linked to PAH Risk
- Ryan Quigley
Targeting Macrophages in Pulmonary Arterial Hypertension
Targeting Macrophages in Pulmonary Arterial Hypertension
Clinician's Roundtable
Targeting Macrophages in Pulmonary Arterial Hypertension
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Clinician's Roundtable
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
AudioAbstracts
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
- Hallie Blevins, PhD
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
AudioAbstracts
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
- Ryan Quigley
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Heart Matters
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Redefining ATTR-CM Care in the Age of Targeted Therapy
Redefining ATTR-CM Care in the Age of Targeted Therapy
On the Frontlines of ATTR-CM
Redefining ATTR-CM Care in the Age of Targeted Therapy
- Steve Jackson, PharmD
- David Rind, MD, MSc
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CM
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
- Shelina Ramnarine, PhD
- Chadi Alraies, MD, MPH, FACC

All Programs

Popular

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy